SMARCB1 and cancer: Although the significance of discordant cancers is controversial, patients with discordant cases demonstrate a borderline significant trend toward survival differences compared to those with concordant cases, which may be a potential therapeutic strategy for discrepant tonsil cancers with SMARCB1 mutation [47,48,49].